-
公开(公告)号：US20240316106A1
公开(公告)日：2024-09-26
申请号：US18583213
申请日：2024-02-21
申请人： AstraZeneca AB
IPC分类号： A61K35/17 , A61K39/00 , A61P35/00 , C07K14/05 , C07K14/47 , C07K14/82 , C12N5/0783 , C12N9/22 , C12N15/11 , C12N15/86
CPC分类号： A61K35/17 , A61K39/4611 , A61K39/4631 , A61K39/464452 , A61K39/464457 , A61K39/464464 , A61P35/00 , C07K14/05 , C07K14/4703 , C07K14/82 , C12N5/0636 , C12N9/22 , C12N15/111 , C12N15/86 , C12N2310/20 , C12N2740/15043
摘要： The disclosure relates to methods, cells, and compositions for preparing cell populations and compositions for adoptive cell therapy. In particular, provided herein are methods for expansion and proliferation of primary immune cells including T cell populations.
-
公开(公告)号：US20240309101A1
公开(公告)日：2024-09-19
申请号：US18470875
申请日：2023-09-20
发明人： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C12N15/85
CPC分类号： C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
摘要： The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US11851494B2
公开(公告)日：2023-12-26
申请号：US16979931
申请日：2019-03-13
发明人： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Sergio Quezada
IPC分类号： C07K16/28 , A61P35/02 , C12N15/85 , A61P35/00 , A61K39/395 , C07K14/55 , A61K45/06 , A61K39/00 , C07K14/05
CPC分类号： C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
摘要： The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US11840558B2
公开(公告)日：2023-12-12
申请号：US17357444
申请日：2021-06-24
申请人： AMGEN INC.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号： C07K14/05 , A61K38/1825 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US20230277619A1
公开(公告)日：2023-09-07
申请号：US18067940
申请日：2022-12-19
申请人： SANOFI
发明人： Gary J. Nabel , Chih-Jen Wei , Laura Nguyen , Kurt Swanson , Te-Hui Chou , Stefan Koester
CPC分类号： A61K38/162 , A61K47/00 , C07K14/05 , C07K2319/00
摘要： This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.
-
公开(公告)号：US20160199479A1
公开(公告)日：2016-07-14
申请号：US15017765
申请日：2016-02-08
申请人： IMMUNOCORE LIMITED
发明人： Qin SU , Peter MOLLOY , Nathaniel LIDDY
CPC分类号： C07K14/05 , A61K39/12 , A61K2039/6056 , C07K14/7051 , C07K16/2809 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/30 , C12N7/00 , C12N2710/16222 , C12N2710/16234 , C12N2710/16271
摘要： The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted CLGGLLTMV peptide (SEQ ID NO: 1) derived from the LMP2A protein from Epstein Barr Virus (EBY). TCRs of the invention comprise a TCR alpha chain variable domain and/or a TCR beta variable domain. Certain preferred TCRs also bind the natural peptide variants SLGGLLTMV (SEQ ID NO: 17) and CLGGLITMV (SEQ ID NO: 18) presented as a peptide-HLA-A2 complex. The TCRs of the invention demonstrate excellent specificity profiles for those LMP2A epitopes and have binding affinities for the complex which result in an enhanced ability to recognize the complex compared to a soluble reference TCR having the extracellular sequence of the native EBY LMP2A TCR alpha chain given in FIG. 3 (SEQ ID No: 4) and the extracellular sequence of the native EBY LMP2A TCR beta chain given in FIG. 4 (SEQ ID No: 5).
摘要翻译： 本发明涉及结合源自爱泼斯坦巴尔病毒（EBY）的LMP2A蛋白质的HLA-A2限制性CLGGLLTMV肽（SEQ ID NO：1）的T细胞受体（TCR）。 本发明的TCR包含TCRα链可变结构域和/或TCRβ可变结构域。 某些优选的TCR还结合作为肽HLA-A2复合物呈现的天然肽变体SLGGLLTMV（SEQ ID NO：17）和CLGGLITMV（SEQ ID NO：18）。 本发明的TCR证实了对于那些LMP2A表位的优异的特异性谱，并且与具有天然EBY LMP2ATCRα链的细胞外序列的可溶性参考TCR相比，复合物具有增强的识别复合物的能力的结合亲和力，其给出在 图。 3（SEQ ID No：4）和图1中给出的天然EBY LMP2ATCRβ链的细胞外序列。 4（SEQ ID No：5）。
-
7.发明授权Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein 有权包含衣壳蛋白前导序列，全长prM蛋白和全长E蛋白的重组登革热病毒抗原公开(公告)号：US09186397B2
公开(公告)日：2015-11-17
申请号：US14204846
申请日：2014-03-11
申请人： Altravax, Inc.
发明人： Doris Apt , Juha Punnonen , Alice M. Brinkman
CPC分类号： A61K39/12 , A61K39/00 , A61K2039/5258 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/57 , C07K14/005 , C07K14/05 , C07K2319/00 , C07K2319/02 , C12N7/00 , C12N15/86 , C12N2750/14143 , C12N2770/24122 , C12N2770/24123 , C12N2770/24134 , C12N2770/24171 , Y02A50/386 , Y02A50/388
摘要： The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
摘要翻译： 本发明提供了由其编码的多核苷酸和多肽，其具有有利的性质，包括诱导对黄病毒的免疫应答的能力。 本发明的多肽和多核苷酸可用于诱导针对黄病毒的免疫应答的方法，包括登革热病毒。 还提供了用于利用本发明的多核苷酸和多肽的组合物和方法。
-
8.发明授权Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies 有权使用抗GBV-C E2抗体抑制HIV-1复制的方法公开(公告)号：US08858946B2
公开(公告)日：2014-10-14
申请号：US12179399
申请日：2008-07-24
CPC分类号： A61K39/29 , A61K2039/505 , C07K14/05 , C07K14/1841 , C07K16/109 , C07K2317/34 , C12N7/00 , C12N2770/24222 , C12N2770/24234
摘要： GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.
摘要翻译： GB病毒C（GBV-C或丙型肝炎病毒）是经常导致人类慢性病毒血症的黄病毒。 本发明提供涉及用于抑制和治疗HIV感染的抗GBV-C抗体或其它GBV-C结合剂或GBV-C抗原的组合物和方法。
-
公开(公告)号：US11873341B2
公开(公告)日：2024-01-16
申请号：US16979932
申请日：2019-03-13
发明人： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Sergio Quezada
IPC分类号： C07K16/28 , A61P35/02 , C12N15/85 , A61P35/00 , A61K39/395 , C07K14/55 , A61K45/06 , A61K39/00 , C07K14/05
CPC分类号： C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
摘要： The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.
-
10.发明申请USE OF PEPTIDES AS TRANSPORTERS INTENDED FOR THE INTERNALIZATION OF MOLECULES OF INTEREST INTO TARGET CELLS 有权作为用于将目标细胞分享利益的内分泌剂用作输送机的肽的使用公开(公告)号：US20130116201A1
公开(公告)日：2013-05-09
申请号：US13643598
申请日：2011-04-07
CPC分类号： C07K14/05 , A61K38/1709 , A61K47/64 , C07K14/005 , C07K14/4702 , C07K2319/10 , C12N2710/16222
摘要： The method pertains to a peptide including the amino acid sequence SEQ ID NO: 1, or a peptide including an amino acid sequence having 93%, in particular 95%, particularly 98% sequence identity homology with the sequence SEQ ID NO: 1, in order to obtain a transporter intended for the internalization of a molecule of diagnostic or therapeutic interest into the target cells.
摘要翻译： 该方法涉及包括氨基酸序列SEQ ID NO：1的肽或包含与SEQ ID NO：1序列具有93％，特别是95％，特别是98％序列同一性同源性的氨基酸序列的肽， 以获得旨在将目标细胞中诊断或治疗兴趣分子内化的转运蛋白。
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.031 秒)
